hrp0084fc6.2 | Gonads & DSD | ESPE2015

A Role for DMRT1 in Human Primary Sex-Determination

Rojo Sandra , Murphy Mark , Lee John , Gearhart Micah , Kurahashi Kayo , Banerjee Surajit , Loeuille Guy-Andre , Zarkower David , Aihara Hideki , Bardwell Vivian , McElreavey Ken , Bashamboo Anu

Background: DMRT transcription factors are highly conserved regulators of metazoan sexual development. The role of DMRT1 in human primary sex-determination is unclear. Chromosome 9p deletions that remove one copy of DMRT1 are associated with 46,XY feminization and gonadal dysgenesis. While they suggest that DMRT1 is haploinsufficient for testicular development, these deletions usually remove other genes, including DMRT2 and DMRT3. Also, most 9p deletions cause incomplete gonad...

hrp0084p2-256 | Diabetes | ESPE2015

Exposure to Phthalates and Phenols in Relation to Gestational Blood Glucose Homeostasis

Fisher Benjamin G. , Frederiksen Hanne , Andersson Anna-Maria , Juul Anders , Thankamony Ajay , Ong Ken K. , Dunger David B. , Hughes Ieuan A. , Acerini Carlo L.

Background: Endocrine disrupting chemicals (EDCs), such as phthalates and bisphenol A (BPA), have been associated with insulin resistance (IR) and type 2 diabetes (T2D) in non-pregnant adults. By contrast, recent pilot studies of pregnant women found negative associations between phthalates and blood glucose, and a lack of association with BPA. No studies have examined gestational IR or secretion in relation to EDC exposure.Objective: To confirm these re...

hrp0084lbp-1267 | Late Breaking Posters | ESPE2015

Safety and Efficacy of Long-Acting GH (VRS-317) in Children with GHD: Effects of Dose Change in the Second Treatment Year

Bright George , Moore Wayne V , Nguyen Huong Jil , Kletter Gad B , Miller Bradley S , Fechner Patricia Y , Ng David , Humphriss Eric , Cleland Jeffrey L

Background: VRS-317, a novel fusion protein of rhGH exhibiting delayed clearance, serum half-life generally >100 h, and potential for once monthly dosing, was previously evaluated in a 6-month phase 1b/2a study of weekly, twice monthly or monthly dosing (5.0 mg/kg per month) in prepubertal GHD children (n=64).Objective and hypotheses: We evaluated whether increased VRS-317 dose from 12 to 18 months can offset the decrease in height velocitie...

hrp0094p1-33 | Fat, Metabolism and Obesity A | ESPE2021

Metabolomics in early life and the association with body composition at age 2 years

van Beijsterveldt Inge , Snowden Stuart , Myers Pernille Neve , Fluiter Kirsten de , Brix Susanne , Ong Ken , Dunger David , Hokken-Koelega Anita , Koulman Albert ,

Background and Objectives: Early life might be a critical window for adiposity programming later in life. Metabolic profile in early life may reflect this programming and correlate with later life adiposity. We investigated if metabolic profile at 3 months of age is predictive for body composition at age 2 years and if there are differences between boys and girls and between infant feeding types.Methods: In 318 healthy t...

hrp0097fc10.1 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) & Multisystem endocrine disorders | ESPE2023

Dasiglucagon safety in paediatric participants with CHI

Meissner Thomas , D. De León Diva , Thornton Paul , Zangen David , Mohnike Klaus , Andersen Marie , Bøge Eva , Birch Sune , Ivkovic Jelena , Banerjee Indi

Background: Congenital hyperinsulinism (CHI) is a rare disorder, which causes persistent and severe hypoglycaemia in infants and children. CHI can be treated with glucagon, but long-term use is challenging owing to its instability in aqueous solution. Dasiglucagon, a stable glucagon analogue designed for long-term use as a subcutaneous continuous infusion, is in clinical development. Here, we present dasiglucagon safety results in participants treated for up t...

hrp0097p1-343 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Facilitating Transition of Care Into Adulthood in Brain Cancer Survivors With Acquired Pediatric Growth Hormone Deficiency: Insights From an Advisory Board

Alter Craig , Boguszewski Margaret , Clemmons David , Dobri Georgiana , Geffner Mitchell , Kelepouris Nicky , Miller Bradley , Oh Rich , Shea Heidi , Yuen

Kevin

Childhood cancer survivors (CCS), particularly brain cancer survivors, are at risk of developing growth hormone deficiency (GHD) due to hypothalamic-pituitary damage from direct tumor mass effects or treatment. Optimization of testing, long-term treatment, and monitoring during care transition from pediatric to adult endocrinology providers remain challenging. A group of endocrinology experts convened to discuss these challenges, the risks and benefits of GH therapy in CCS wit...

hrp0092rfc8.6 | Pituitary, Neuroendocrinology and Puberty Session 1 | ESPE2019

Growth, Pubertal Course and Long-Term Outcome of 46,XY Boys Born with Atypical Genitalia and Low Birthweight

Tack Lloyd , Straaten Saskia van der , Cools Martine , consortium On behalf of the I-DSD

Introduction: Boys born small for gestational age (SGA) often have undermasculinized genitalia. Little is known about the pubertal development and gonadal function on a longer-term in this specific group of males.Aims: To determine the (pubertal) development and long-term urological and endocrine outcome of undermasculinized boys born SGA compared to undervirilized boys born appropriate for gestational age (AGA).<p c...

hrp0092p1-198 | Fat, Metabolism and Obesity (1) | ESPE2019

Correlation of Serum Chemerin Concentrations with Obesity/Metabolic Syndrome Characteristics in Pre-Adolescents and Adolescents

Bacopoulou Flora , Koutroumpa Arsinoi , Zoi Vasiliki , Karatza Eleni , Karalis Vangelis , Markantonis Sophia , Siahanidou Tania

Background: Chemerin, a protein mainly synthesized in the adipose tissue and liver, belongs to the adipokines family and is implicated in signaling for adipocyte differentiation and lipolysis. From this point of view, chemerin can exert an important role in the regulation of various pathophysiological functions, including lipogenesis and metabolism.Objective: The aim of this study was to investigate the relationship betw...

hrp0092p3-62 | Diabetes and Insulin | ESPE2019

What Does the Insulin Pump Change in Children with Type 1 Diabetes? One-Year Clinical Follow-Up

Nezir Engin Muhammet Mesut , Arslanoglu Ilknur , Cangur Sengul

Aim: The insulin pump has an important contribution to quality of life and individualized insulin therapy. However, studies that observe clinical criteria can sometimes only reveal marginal benefits or minor differences. The use of insulin pump in our country has become recently widespread. Therefore, we aimed to share our clinical experience and to examine the effect of the pump on individual cases.Method: The records o...

hrp0082p1-d3-54 | Bone (1) | ESPE2014

Correlation of Sclerostin Levels with Bone Metabolism Markers and Bone Mineral Density in Children and Adolescents with Type 1 Diabetes Mellitus (T1DM)

Tsentidis Charalampos , Gourgiotis Dimitrios , Kossiva Lydia , Marmarinos Antonios , Papathanasiou Asteroula , Doulgeraki Artemis , Karavanaki Kyriaki

Background: Sclerostin is an inhibitor of the Wnt/b-catenin bone metabolic pathway. Increased sclerostin levels and reduced bone mineral density (BMD) have been documented in adult patients with diabetes mellitus (DM), predominantly in those with T2DM. No relevant data exist on childhood T1DM.Objective and hypotheses: Our aim was to study plasma sclerostin concentration in children and adolescents with T1DM and controls and to correlate sclerostin levels...